Combining enzalutamide with an ErbB inhibitor, such as afatinib, may therefore enhance the antitumor effect in GBM cells by jointly targeting AR and ErbB signaling pathways, though more data are needed to confirm the therapeutic impact of this approach [82]. Here, AR is linked to glioblastoma.